Structure via PubChem · Public domain (PubChem)
temafloxacin
Sign in to saveAlso known as Temafloxacina, Temafloxacine, Temafloxacinum
Temafloxacin (marketed by Abbott Laboratories as Omniflox) is a fluoroquinolone antibiotic drug which was withdrawn from sale in the United States shortly after its approval in 1992 because of serious adverse effects resulting in three deaths. It is not marketed in Europe.
Chemical data
- Formula
- C21H18F3N3O3
- Molecular weight
- 417.4 g/mol
- IUPAC name
- 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
- SMILES
- CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
- InChIKey
- QKDHBVNJCZBTMR-UHFFFAOYSA-N
- XLogP
- 0.6
- Polar surface area
- 72.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 9
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1992
- Indications
- bacterial disease
via ChEMBL · EBI
Research
275 papersvia PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 417.130026
- Has use
- medication
Show 5 more facts
- chemical formula
- C₂₁H₁₈F₃N₃O₃
- subject has role
- antibiotic
- canonical SMILES
- CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
- defined daily dose
- 0.8
- Commons category
- Temafloxacin
Sources (3)
via Wikidata · CC0
~2 min read
Encyclopedic overview
6 sectionsContents
- History
- Pharmacokinetics
- Clinical uses
- See also
- References
- External links
Temafloxacin (marketed by Abbott Laboratories as Omniflox) is a fluoroquinolone antibiotic drug which was withdrawn from sale in the United States shortly after its approval in 1992 because of serious adverse effects resulting in three deaths. It is not marketed in Europe.
== History == Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the United States by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in over 100 patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.
Excerpted from Wikipedia’s “temafloxacin” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0